Anuh Pharma Ltd
Anuh Pharma Ltd Q1 FY27 Results & Presentation Highlights: Revenue, Margins & Capex
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Anuh Pharma Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY27 Operating Revenue: Rs. EBITDA for Q1 FY27: Rs.
From Anuh Pharma Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY27 Operating Revenue: Rs. 193.81 Cr, up 3.93% YoY from Rs. 186.48 Cr in Q1 FY26 (Page 6, 8).
- Production Volume: 491 MT, up 19.46% YoY from 411 MT in Q1 FY26 (Page 6).
- Operating Profit: Rs. 38.15 Cr, up 39.50% YoY (Page 8).
- Revenue by Product Groups and Customers: Detailed product-wise revenues and customer concentration referenced but specific figures focus on totals only for Q1 FY27 vs Q1 FY26 (Pages 10-13).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The presentation does not specify exact capex amounts or timelines for new plants or projects.
- Future Outlook (Page 28) mentions "continued investments in compliance, operational efficiency and capacity enhancement."
- Growth strategy includes "extensive volume expansions across API lines."
- Infrastructure section highlights existing facilities: Tarapur manufacturing complex (11,400 sq. m) with 9 API blocks and 2 intermediate blocks; 10,000 sq. ft. R&D facility at Mahape, Navi Mumbai, DSIR approved.
- No explicit new plant or project launch dates or capex figures are provided.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Anuh Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹202 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Beta Drugs Ltd (Q1 FY27)
Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Key investor presentation takeaways from Beta Drugs Ltd's Q1
- NGL Fine Chem Ltd (Q1 FY27)
Quarterly Revenue (Q1FY27):** ₹139.16 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q1 FY27 investor presentation — and how it ranks aga
- Shree Ganesh Remedies Ltd (Q1 FY27)
Q1FY27 Revenue from Operations: ₹14.36 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY27 investor presentation — and how it rank
- Bharat Parenterals Ltd (Q1 FY27)
Consolidated Revenue Q1 FY27:** ₹93.7 Cr, down 19.2% YoY from ₹116.0 Cr in Q1 FY26. Key investor presentation takeaways from Bharat Parenterals Ltd's Q1 FY27 in
Frequently Asked Questions
What were Anuh Pharma Ltd Q1 FY27 results?
Q1 FY27 Operating Revenue: Rs. EBITDA for Q1 FY27: Rs.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
The presentation does not specify exact capex amounts or timelines for new plants or projects. - Future Outlook (Page 28) mentions "continued investments in compliance, operational efficiency and capacity enhancement." - Growth strategy includes "extensive volume expansions across API lines." - Infrastructure section highlights existing facilities: Tarapur manufacturing complex (11,400 sq.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.